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A simple protocol for the synthesis of a ganglioside Hp-s1 (1) starting from commercially available
phytosphingosine, sialic acid, and D-glucose is described. This synthesis involved a glycosylation reaction
of a phytosphingosine derived acceptor with a highly active benzyl protected glucosyl donor, a second
glycosylation of a glucosyl acceptor with a sialyl donor followed by Staudinger reaction, amidation, and
global deprotection as key steps.Introduction
Gangliosides are well-known glycosphingolipids in which one
or more sialic acids is linked on the sugar chain. Being part of
tissues, body uids and nervous system, gangliosides play
important roles in biological systems1 and also behave as
scavengers in the body to repair and regenerate neurons and to
suppress neuronal diseases.2 Gangliosides have been found to
be inhibitory agents towards Alzheimer's disease, Parkinson's
disease, Guillain–Barre´ syndrome, and Huntington's disease
and studied well in stem cell biology.3 In biological system,
synthesis of such molecules take place primarily in the endo-
plasmic reticulum, and the sequential addition of carbohydrate
moieties on the existing acceptor lipid takes place in the Golgi
apparatus.4 Recent studies revealed that on the cell surface,
gangliosides are involved in cell–cell recognition,5 cell diﬀer-
entiation,6 and signal transduction.7 Marine invertebrates are
the major source for ganglioside extraction, and these extracts
have shown neuritogenic activity toward the rat pheochromo-
cytoma cell line PC-12 in the presence of nerve growth factor.
Recently, it was observed that ganglioside Hp-s1 (1) shows
superior neuritogenic activity (34%) than that of mammalian
ganglioside GM1 (25.4%).8 At the same time, GM1 has a more
complex structure, and there are synthetic diﬃculties for the
preparation of this molecule.9 Due to the multidimensional
importance of gangliosides, recently the synthesis of these
molecules has attracted much attention, although few gangli-
osides, i.e. M5, HLG-2, and LLG-3, have been synthesized by
various groups.10 Recently, Ye and co-workers also reported the
stereoselective synthesis of a trisaccharide moiety of ganglio-
side HLG-2.11Hsing University, Taichung 402, Taiwan.
886-4-22862547; Tel: +886-4-22840411
tion (ESI) available. See DOI:
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1Ganglioside Hp-s1 (1) (Fig. 1) is isolated from the ovary of the
sea urchin Diadema setosum or the sperm of the sea urchin
Hemicentrotus pulcherrimus.12 The structure of ganglioside Hp-
s1 possesses Neu5Ac a2/ 6Glcb1/ 1Cer. The synthesis and
bioassay of ganglioside Hp-s1 (1) has received much less
attention from the scientic community. Recently, Tsai et al.
synthesized an analogue of ganglioside Hp-s1, which has one
less carbon than Hp-s1 in the carbon chain of the phytos-
phingosine segment, and found that this analogue of ganglio-
side Hp-s1 exhibits neuritogenic activity toward the human
neuroblastoma cell line SH-SY5Y in the absence of nerve growth
factor (NGF).13 Due to the reduced availability of gangliosides
from natural sources, in continuation of our long ongoing
research program on carbohydrate chemistry,14 we selected the
ganglioside Hp-s1 as our target molecule and report the rst
total synthesis of ganglioside Hp-s1 (1) from commercially
available sialic acid, D-glucose, phytosphingosine, and D-lyxose.Results and discussion
The structure of a ganglioside consists of two major segments,
i.e. a glycan part and a ceramide part. A survey of the literature
revealed that there are several approaches available to connect
these two segments. Mostly, two major approaches have been
used for this purpose, i.e. (i) pre-incorporation of phytos-
phingosine at the reducing end of the glycan chain followed by
assembly of the ceramide structure (non-reducing end to
reducing end),13 or (ii) glycosylation of the ceramide part withFig. 1 The structure of ganglioside Hp-s1 (1).
This journal is © The Royal Society of Chemistry 2014
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View Article Onlinethe full-length glycan part, which yields a ganglioside frame-
work (reducing end to non-reducing end) directly.15 It has been
observed that the reducing end to non-reducing end approach
can oﬀer high eﬃciency for small ganglioside syntheses.
Accordingly, our retrosynthetic strategy for the synthesis of 1
can follow the sequences as shown in Scheme 1. The target
compound 1 can be obtained from compound 2 through a
Staudinger reaction, followed by amide bond formation with 3
and global deprotection. Compound 2 can be prepared via the
glycosylation of sialyl donor 5 and glycosyl acceptor 4. The
glycosylation between glucosyl donor 7 and the phytosphingo-
sine derived acceptor 6 can provide glycosyl acceptor 4.
As our retrosynthetic strategy shows, initially our aim was to
synthesize the phytosphingosine derived acceptor 6 and glu-
cosyl donor 7. In this regard, rst we turned our attention
towards the synthesis of acceptor 6 (Scheme 2). We envisaged
that the acceptor 6 can be prepared from commercially available
phytosphingosine 8 and D-lyxose 12. Since both starting mate-
rials contain all the requisite chiral centers that are necessary
for the acceptor 6, therefore, we selected these commercially
available chemicals for the synthesis of 6. Accordingly, phytos-
phingosine 8 (ref. 14a and b and 16) was treated with triyl
azide (TfN3) in the presence of K2CO3 and a catalytic amount of
copper sulfate pentahydrate, which produced 2-azidoScheme 1 Retrosynthesis of ganglioside Hp-s1 (1).
Scheme 2 Synthesis of acceptor 6 from phytosphingosine 8 and D-
lyxose 12.
This journal is © The Royal Society of Chemistry 2014phytosphingosine 9 in 85% yield.17 The protection of the
primary alcohol functionality of 9 was carried out using t-
butylchlorodiphenylsilane (TBDPSCl), triethylamine, and 4-di
methylaminopyridine (DMAP) to furnish diol 10 in 93% yield.18
The secondary alcohol group of diol 10 was protected by using
2,2-dimethoxypropane (2,2-DMP) and a catalytic amount of p-
toluenesulfonic acid (PTSA) followed by TBAF cleavage of the
silane group, which provided the phytosphingosine derived
acceptor 6 in excellent yield in two steps (Path A, Scheme 2).17
Since phytosphingosine 8 is an expensive compound, we also
found an alternative approach for the synthesis of 6 where we
start this synthesis from the cheaper compound D-lyxose 12. In
this alternative strategy (Path B, Scheme 2), the acetonide
protection of the C2–C3 diol of D-lyxose 12, followed by TBDPS
protection of the primary alcohol produced hemiacetal 13 in
75% yield in a one-pot operation. Hemiacetal 13 was then
treated with Wittig salt (C13H27PPh3Br) in the presence of more
hindered base LiHMDS at 0 C, providing olen 14 in good
yield.14c,19 Compound 15 was obtained by hydrogenation ofRSC Adv., 2014, 4, 47752–47761 | 47753
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View Article Onlineolen 14 using Pd/C and hydrogen gas. C-2 epimerization of
mono-ol 15 was achieved under Mitsunobu conditions, and the
TBAF removal of the silane group provided phytosphingosine
derived acceptor 6 in good yield in a one-pot synthesis.16b It is
worth mentioning here that the Wittig salt (C13H27PPh3Br) used
in this alternative path is inexpensive.
The glucosyl acceptors 7a–7d were synthesized following the
literature procedures.20 Once we had the segments 6 and 7 in
hand, now our target was to couple them. For this, in order to
achieve high yield and selectivity, we optimized the best
conditions for glycosylation21 of acceptor 6 with various donors
7a–7d. At rst, the application of anchimeric assistance in these
reactions of glucosyl donors 7a–7c with acceptor 6 was opti-
mized. In the beginning, thioglucoside donor 7a (ref. 20a) was
reacted with acceptor 6 in the presence of NIS/TfOH at DCM at
20 C to furnish the b-stereoisomer 16a in 38% yield (entry 1,
Table 1). To enhance to chemical yield of 16a, imidate donor 7b
(ref. 20b and 22) was treated with acceptor 6 in the presence of
TMSOTf, which provided only b stereoisomer in 36% yield
(entry 2, Table 1). Next, a similar reaction of thioglucoside 7c
(ref. 20c) having a benzyl group at C3 position was carried out
with acceptor 6, producing compound 16b in 46% yield (entry 3,
Table 1). In the above entries, the low chemical yield of 16amayTable 1 Optimized conditions for glycosylation of acceptor 6 with vario
entry Donor Promoter Solven
1 7aa NIS/TfOH DCM
2 7ba TMSOTf DCM
3 7ca NIS/TfOH DCM
4 7db TMSOTf DCM/
5 7db TMSOTf DCM/
6 7dc TMSOTf DCM/
7 7dc TMSOTf DCM/
8 7dc TMSOTf DCM/
a 1.3 equiv. b 2.0 equiv. c 2.5 equiv.
47754 | RSC Adv., 2014, 4, 47752–47761be due to the lesser reactivity of donors' 7a–7c. Anchimeric
assistance could not provide a higher yield of the compounds
16a and 16b. However, the glycosylation of disarmed donors
(7a–c) reacted with acceptor 6 to provide 16a and 16b in lower
yield.
To increase the yield and selectivity, we turned our attention
to study the solvent eﬀect using 7d (ref. 20d) as our glucosyl
donor. In this regard, imidate 7d was allowed to react with
acceptor 6 in the presence of TMSOTf to provide the corre-
sponding glycosylated products (a-isomer and b-isomer), which
contain an acetyl group at the C-6 position of the glucosyl
donor.23 However, the glycosylated products (a-isomer and b-
isomer) and acceptor 6 have similar polarity in TLC, which
caused diﬃculty in separation via column chromatography.
Fortunately, we could separate the product 17 (b-isomer), a-
isomer and acceptor 6 aer deacetylation through column
chromatography. Interestingly, we obtained a compound 17 as a
mixture of stereoisomers (b : a ¼ 2 : 1) at 30 C in 48% yield
(entry 4, Table 1). Next, we tried to improve the yield and
selectivity over the b–a mixture. Variation in the temperature
from 30 C to room temperature in the similar reaction
improved the yield of compound 17 to 54% with no change in
stereoselectivity (entry 5, Table 1). Other entries (entry 6 and 7,us donors 7a–7d
t T (C) Product (yield, b/a)
20 16a (38%, b only)
20 16a (36%, b only)
20 16b (46%, b only)
ACN (1/2) 30 17 (48%, 2.0/1)
ACN (1/2) 30 C to rt 17 (54%, 2.0/1)
ACN (1/2) rt 17 (60%, 1.0/1)
ACN (1/2) 0 C to rt 17 (66%, 1.5/1)
ACN (1/2) 30 C to rt 17 (82%, 3.2/1)
This journal is © The Royal Society of Chemistry 2014
Table 2 Optimized conditions for glycosylation of acceptor 17 with
various donors 5a–5d
Entry Donor Promoter Product (yield, ab/bb)
1 5a NIS/TfOH 18a (86%, 2.7/1)
2 5b NIS/TfOH 18a (84%, 3.9/1)
3 5c AgOTf 18a (29%, 2.6/1)
4 5d NIS/TfOH 18b (54%, 1.6/1)
5 5d NIS/TMSOTf 18b (77%, 2.0/1) Scheme 3 Finalized synthesis of target molecule 1.
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View Article OnlineTable 1) with changes in the temperature did not provide the
expected yield of compound 17 with a b : a ratio. Finally,
glycosylation reaction of imidate donor 7d (2.5 equiv.) and
acceptor 6 (1 equiv.) was carried out in the presence of TMSOTf
and 3 A˚ molecular sieves in DCM/ACN solvent at30 C to room
temperature (entry 8, Table 1), giving the corresponding
compound 17 in 82% overall yield in two steps.
Next we synthesized various sialyl donors (5a–5d) according
to the procedures available in the literature.24–27 Then, we per-
formed the glycosylation between various sialyl donors (5a–5d)
and glycosyl acceptor 17 using diﬀerent promoters as shown in
Table 2. Accordingly, rst, sialyl donor 5a (ref. 24) was treated
with acceptor 17 in the presence of N-iodosuccinimide (NIS)
and triuoromethanesulfonic acid (TfOH) using DCM and ACN
solvent system at30 C, providing compound 18a in 86% yield
(ab/bb ¼ 2.7/1, entry 1, Table 2). Similarly, sialyl donor 5b (ref.
25) on treatment with acceptor 17 in the presence of NIS and
TfOH under same reaction conditions furnished compound 18a
in 84% yield (ab/bb ¼ 3.9/1, entry 2, Table 2). When AgOTf was
used for glycosylation reaction between sialyl donor 5c (ref. 26)
with acceptor 17 in similar conditions (entry 3, Table 2), we
obtained compound 18a in comparatively lower yield (29%)
with bad selectivity. Previously, sialyl donor 5d was found to be
a suitable donar for glycosylation reaction, resulting in high
selectivity with good yields.27 However, when we treated sialyl
donor 5d (ref. 27) with acceptor 17 under the inuence of NIS
and TfOH, the reaction provided the corresponding compound
18b in 54% yield (ab/bb ¼ 1.6/1, entry 4, Table 2). A change in
the promoter from NIS/TfOH to NIS/TMSOTf for the glycosyla-
tion reaction between sialyl donor 5d with acceptor 17 aﬀorded
18b in 77% yield (ab/bb ¼ 2.0/1, entry 5, Table 2).This journal is © The Royal Society of Chemistry 2014Next, we subjected the compound 18a to sequential Stau-
dinger reaction and amide bond formation as shown in Scheme
3, which provided 19 in 51% overall yield in two steps. The
deprotection of the acetyl, benzyl, and acetonide groups of
compound 19 provided the target molecule ganglioside Hp-s1
(1) in 85% yield.Conclusions
We have developed the rst synthesis of ganglioside Hp-s1 (1)
with overall yields of 21.5% and 9.6%, starting from phytos-
phingosine or D-lyxose, respectively, in 10 steps. In the assembly
of the glycan part, Neu5Aca2/ 6Glcb1/ 1Cer, the three chiral
carbons of the ceramide part were each eﬃciently established in
a stereoselective manner from commercially available phytos-
phingosine and D-lyxose. The nal connection of the glycan and
ceramide parts was accomplished with relatively high yield. The
short and eﬃcient route described here for the synthesis of
ganglioside Hp-s1 is expected to provide access to other struc-
turally related glycolipids for exploring their neuritogenic
activities and other biological properties.Experimental section
General information
Some reactions were conducted in ame-dried glassware, under
a nitrogen atmosphere. Dichloromethane, tetrahydrofuran, and
N,N-dimethylformamide were puried and dried from a safe
purication system containing activated Al2O3. All reagents
obtained from commercial sources were used withoutRSC Adv., 2014, 4, 47752–47761 | 47755
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View Article Onlinepurication, unless otherwise mentioned. Phytosphingosine
was purchased from Tokyo Chemical Industry Co. Ltd, Japan,
and D-lyxose was purchased from Carbosynth China Ltd, China.
Flash column chromatography was carried out on silica gel 60
(230–400 mesh, E. Merck). TLC was performed on pre-coated
glass plates of silica gel 60 F254 (0.25 mm, E. Merck); detection
was executed by spraying with a solution of Ce(NH4)2(NO3)6 (0.5
g), (NH4)6Mo7O24 (24 g) and H2SO4 (28 mL) in water (500 mL)
and subsequent heating on a hot plate. Optical rotations were
measured at 589 nm (Na) at 27 C. 1H, 13C NMR, DEPT,
1H-1HCOSY, 1H-13C COSY, and NOESY spectra were recorded
with 400 and 600 MHz instruments. Chemical shis are in ppm
from Me4Si generated from the CDCl3 lock signal at d 7.26. IR
spectra were taken with a FT-IR spectrometer using KBr plates.
Mass spectra were analyzed on Orbitrap instrument with an ESI
source.
(2S,3S,4R)-2-Azido-octadecan-1,3,4-triol (9). Amixed solution
of NaN3 (2.04 g, 31.50 mmol), DCM (5 mL) and water (5 mL) was
cooled at 0 C, and Tf2O (1.10 mL, 6.30 mmol) was added
dropwise over 20 min. Aer the reaction mixture was stirred for
3 h, the mixture was extracted with DCM (2  8 mL). The
combined organic layer was washed with saturated NaHCO3 (16
mL) to form a combined organic layer, which contained TfN3.
To a suspension of phytosphingosine (1.00 g, 3.15 mmol),
K2CO3 (2.14 g, 15.75 mmol) and CuSO4$5H2O (16 mg, 0.01
mmol) in a mixture of methanol (4 mL) and water (3 mL) was
added to the combined organic layer, which contained TfN3.
The reaction mixture was stirred for 12 h. Aer the reaction was
completed, the resulting solution was concentrated to remove
the organic solvent under vacuum. The mixture was extracted
with EtOAc (2  24 mL), and the combined organic layers were
dried over anhydrous MgSO4, ltered, and concentrated under
reduced pressure. The residue was recrystallized with EtOH to
give the triol 9 (917 mg) in 85% yield as a white solid. Rf 0.50
(EtOAc/Hex ¼ 1/1); [a]26D +4.5 (c 0.85, MeOH); mp 97 C; IR (KBr)
v 3343, 2918, 2848, 2118, 1463 cm1; 1H NMR (600 MHz,
CD3OD) d 3.92 (dd, J¼ 10.8, 3.0 Hz, 1H, H-1a), 3.75 (dd, J¼ 10.8,
7.8 Hz, 1H, H-1b), 3.59 (ddd, J ¼ 7.8, 4.2, 3.0 Hz, 1H, H-2), 3.54–
3.50 (m, 2H, H-3, H-4), 1.70–1.66 (m, 1H, H-5a), 1.57–1.54 (m,
1H, H-5b), 1.41–1.25 (m, 24H, CH2), 0.89 (t, J¼ 7.2 Hz, 3H, CH3);
13C NMR (150 MHz, CD3OD) d 76.0 (CH), 72.8 (CH), 66.7 (CH),
62.5 (CH2), 33.9 (CH2), 33.1 (CH2), 30.8 (CH2  8), 30.5 (CH2),
26.7 (CH2), 23.7 (CH2), 14.5 (CH3); HRMS (ESI, M + Na
+) calcd
for C18H37O3N3Na 366.2727, found 366.2723.
(2S,3S,4R)-2-Azido-1-O-tert-butyldiphenylsilyl-octadecan-1,3,
4-triol (10). To a solution of 2-azido phytosphingosine 9 (100
mg, 0.29 mmol) in DCM (1.4 mL) and DMF (0.3 mL) were added
Et3N (0.10 mL, 0.73 mmol), DMAP (1 mg, 0.01 mmol) and
TBDPSCl (93 mL, 0.35 mmol) at 0 C. The reaction mixture was
stirred at room temperature for 24 h and then diluted with
EtOAc (10 mL). The organic layers were washed with brine (5
mL), dried over MgSO4, ltered, and concentrated under
reduced pressure. The residue was puried by column chro-
matography on silica gel to give the compound 10 (155.7 mg) in
93% yield as a colorless oil. Rf 0.53 (EtOAc/Hex¼ 1/4); [a]26D +16.4
(c 1.0, CH2Cl2); IR (CH2Cl2) v 3425, 2926, 2855, 2099, 1466, 1428,
1113 cm1; 1H NMR (400 MHz, CDCl3) d 7.72–7.69 (m, 4H, ArH),47756 | RSC Adv., 2014, 4, 47752–477617.47–7.38 (m, 6H, ArH), 4.03 (dd, J¼ 10.8, 4.2 Hz, 1H, H-1a), 3.92
(dd, J¼ 10.8, 6.0 Hz, 1H, H-1b), 3.70–3.66 (m, 2H, H-3, H-4), 3.57
(ddd, J ¼ 6.0, 4.2, 4.2 Hz, 1H, H-2), 1.57 (bs, 2H, OH), 1.56–1.40
(m, 2H, H-5a, H-5b), 1.26 (bs, 23H, CH2), 1.08 (s, 9H, CH3), 0.88
(t, J ¼ 6.6 Hz, 3H, CH3); 13C NMR (150 MHz, CDCl3) d 135.6 (CH
 4), 132.5 (C), 132.4 (C), 130.0 (CH  2), 127.9 (CH  3), 74.1
(CH), 72.3 (CH), 64.1 (CH2), 63.4 (CH), 31.9 (CH2), 31.8 (CH2),
29.7 (CH2  3), 29.6 (CH2  3), 29.3 (CH2  3), 26.7 (CH3  3),
25.6 (CH2), 22.7 (CH2), 19.1 (C), 14.1 (CH3); HRMS (ESI, M + Na
+)
calcd for C34H55O3N3NaSi 604.3905, found 604.3912.
(2S,3S,4R)-2-Azido-1-O-tert-butyldiphenylsilyl-3,4-O-isopro-
pylidene-octadecan-1,3,4-triol (11). To a solution of the diol 10
(155 mg, 0.27 mmol) in acetone (8 mL) were added 2,2-di-
methoxypropane (338 mL, 2.70 mmol) and PTSA (6 mg, 0.03
mmol). The reaction mixture was stirred for 3 h at room
temperature and neutralized with Et3N at 0 C. The reaction
mixture was concentrated under reduced pressure. The residue
was puried by column chromatography on silica gel to give the
product (166 mg) in 99% yield as a colorless oil. Rf 0.61 (EtOAc/
Hex¼ 1/20); [a]26D +11.9 (c 1.0, CH2Cl2); IR (CH2Cl2) v 2957, 2927,
2855, 2099, 1465, 1428, 1113 cm1; 1H NMR (600 MHz, CDCl3) d
7.74–7.70 (m, 4H, ArH), 7.45–7.38 (m, 6H, ArH), 4.12 (ddd, J ¼
9.6, 4.8, 2.4 Hz, 1H, H-4), 4.03 (dd, J ¼ 10.8, 2.4 Hz, 1H, H-1a),
3.94 (dd, J¼ 10.2, 6.0 Hz, 1H, H-3), 3.84 (dd, J¼ 10.8, 6.6 Hz, 1H,
H-1b), 3.42 (ddd, J¼ 9.6, 6.6, 2.4 Hz, 1H, H-2), 1.62–1.47 (m, 2H,
CH2), 1.38–1.26 (m, 30H, CH2, CH3), 1.08 (s, 9H, CH3), 0.88 (t, J
¼ 7.2 Hz, 3H, CH3); 13C NMR (150 MHz, CDCl3) d 135.7 (CH 
4), 133.0 (C), 132.9 (C), 129.8 (CH), 129.7 (CH), 127.7 (CH  4),
108.1 (C), 77.8 (CH), 75.2 (CH), 65.3 (CH2), 61.7 (CH), 31.9 (CH2),
29.7 (CH2  6), 29.6 (CH2  2), 29.4 (CH2  2), 28.1 (CH3), 26.7
(CH3  3), 26.4 (CH2), 25.7 (CH3), 22.7 (CH2), 19.1 (C), 14.1
(CH3); HRMS (ESI, M + Na
+) calcd for C37H59O3N3NaSi 644.4218,
found 644.4213.
5-O-tert-Butyldiphenylsilyl-2,3-O-isopropylidene-D-lyxofura-
nose (13). To a solution of D-lyxose 12 (200 mg, 1.33 mmol) in
acetone (2 mL) was added H2SO4 (7.0 mL, 0.13 mmol) at 0 C.
The reaction mixture was warmed to room temperature and
kept stirring until a clear solution was achieved. Then imidazole
(362 mg) dissolved in dichloromethane (2 mL) and tert-butyl-
chlorodiphenylsilane (388 mL) was added to the clear solution at
0 C. The reaction mixture was warmed to room temperature
and stirred for 3 h. Aer completion, the reaction mixture was
concentrated under reduced pressure to aﬀord a residue. The
residue was diluted with water (10 mL) and extracted with
dichloromethane (3  10 mL). The organic layer was dried over
anhydrous MgSO4, ltered, and concentrated to aﬀord a
residue. The residue was puried by column chromatography
on silica gel to give the product 13 (426 mg, 75%) as a colorless
oil. Rf 0.58 (EtOAc/Hex ¼ 1/3); [a]26D +2.83 (c 1.0, CH2Cl2); IR
(CH2Cl2) v 3473, 3072, 3050, 2937, 2890, 2859, 1468, 1428, 1377,
1210, 1108 cm1; 1H NMR (400 MHz, CDCl3) d 7.73–7.67 (m, 4H,
ArH), 7.44–7.35 (m, 6H, ArH), 5.37 (d, J ¼ 1.6 Hz, 1H, H-1), 4.75
(dd, J ¼ 5.6, 3.2 Hz, 1H, H-3), 4.59 (d, J ¼ 6.4 Hz, 1H, H-2), 4.32
(ddd, J ¼ 10.0, 6.4, 4.0 Hz, 1H, H-4), 3.99 (dd, J ¼ 10.8, 5.6 Hz,
1H, H-5a), 3.90 (dd, J ¼ 10.4, 6.4 Hz, 1H, H-5b), 2.31 (bs, 1H,
OH), 1.35 (s, 3H, CH3), 1.29 (s, 3H, CH3), 1.06 (s, 9H, CH3);
13C
NMR (100 MHz, CDCl3) d 135.64 (CH  2), 135.58 (CH  2),This journal is © The Royal Society of Chemistry 2014
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View Article Online133.4 (C  2), 129.58 (CH), 129.57 (CH), 127.6 (CH  2), 127.5
(CH  2), 112.3 (C), 101.2 (CH), 85.4 (CH), 80.8 (CH), 79.7 (CH),
62.0 (CH2), 26.7 (CH3  3), 25.9 (CH3), 25.0 (CH3), 19.2 (C);
HRMS (ESI, M + Na+) calcd for C24H32O5NaSi 451.1911, found
451.1907.
(2R,3S,4R)-1-tert-Butyldiphenylsilyl-3,4-O-isopropylideneoc-
tadec-5-ene-1,2,3,4-tetraol (14). A solution of hemiacetal 13 (275
mg, 0.64 mmol) and tridecanyltriphenylphosphonium bromide
(1.35 g, 2.57mmol) in anhydrous THF (2.8 mL) was cooled down
to 0 C under nitrogen. A 1 M solution of lithium hexame-
thyldisilylamide in THF (2.6 mL, 2.57 mmol) was slowly added
to the mixture, and the reaction solution was kept stirring for
overnight at 0 C. Aer completion of the reaction, water (10
mL) was added to quench the reaction and the mixture was
extracted with EtOAc (3  10 mL). The combined organic layers
were dried over anhydrous MgSO4, ltered, and concentrated in
vacuo to aﬀord a residue. The residue was puried by column
chromatography to aﬀord the olen 14 (336 mg, 88%, Z/E ¼
2.75/1). Rf 0.49 (EtOAc/Hex ¼ 1/9); [a]27D 5.7 (c 1.0, CH2Cl2); IR
(CH2Cl2) v 3523, 2927, 2855, 1465, 1428, 1374, 1112 cm
1; 1H
NMR (400 MHz, CDCl3) d 7.68–7.64 (m, 4H, ArH), 7.45–7.34 (m,
6H, ArH), 5.70–5.57 (m, 2H, CH]CH), 4.50 (dd, J ¼ 8.0, 6.8 Hz,
1H, H-4), 4.26 (dd, J¼ 6.8, 3.6 Hz, 1H, H-3), 3.71–3.61 (m, 3H, H-
1a, H-1b, H-2), 2.44 (d, J ¼ 6.0 Hz, 1H, 2-OH), 2.05–1.95 (m, 2H,
CH2), 1.50 (s, 3H, CH3), 1.38 (s, 3H, CH3), 1.34–1.22 (m, 20H,
CH2), 1.06 (s, 9H, CH3), 0.88 (t, J ¼ 6.8 Hz, 3H, CH3); 13C NMR
(100 MHz, CDCl3) d 137.5 (CH), 135.6 (CH  2), 135.5 (CH  2),
133.2 (C), 133.1 (C), 129.8 (CH), 129.7 (CH), 127.72 (CH  2),
127.68 (CH 2), 125.4 (CH), 108.2 (C), 78.9 (CH), 77.0 (CH), 70.0
(CH), 64.7 (CH2), 32.2 (CH2), 31.9 (CH2), 29.7 (CH2  2), 29.62
(CH2), 29.58 (CH2), 29.4 (CH2), 29.3 (CH2), 29.2 (CH2), 28.9
(CH2), 27.2 (CH3), 26.8 (CH3  3), 24.9 (CH3), 22.7 (CH2), 19.2
(C), 14.1 (CH3); HRMS (ESI, M + Na
+) calcd for C37H58O4NaSi
617.3997, found 617.4010.
(2R,3S,4R)-1-O-tert-Butyldiphenylsilyl-3,4-O-isopropylidene-
octadecan-1,2,3,4-tetraol (15). A mixture of olen 14 (310 mg,
0.52 mmol), 10% palladium on charcoal (62 mg) and ethyl
acetate (3.1 mL) was stirred under hydrogen gas at room
temperature for 8 h. The Pd/C was removed through celite. The
ltrate was concentrated to give the residue. The residue was
puried by column chromatography on silica gel to aﬀord
compound 15 (248 mg, 80%) as a colorless oil. Rf 0.45 (EtOAc/
Hex ¼ 1/10); [a]27D 11.47 (c 1.0, CH2Cl2); IR (CH2Cl2) v 3687,
2927, 2855, 1465, 1428, 1111 cm1; 1H NMR (400 MHz, CDCl3)
d 7.69–7.65 (m, 4H, ArH), 7.45–7.36 (m, 6H, ArH), 4.18 (dd, J ¼
6.8, 2.8 Hz, 1H, H-3), 4.12 (ddd, J ¼ 9.6, 6.4, 3.6 Hz, 1H, H-4),
3.74–3.63 (m, 3H, H-1a, H-1b, H-2), 2.37 (d, J¼ 5.6 Hz, 1H, OH),
1.76–1.68 (m, 1H, CH2), 1.56–1.43 (m, 5H, CH2, CH3), 1.37 (s,
3H, CH3), 1.32–1.23 (m, 23H, CH2), 1.06 (s, 9H, CH3), 0.88 (t, J
¼ 6.8 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3) d 135.6 (CH 
2), 135.5 (CH  2), 133.2 (C  2), 129.8 (CH), 129.7 (CH),
127.72 (CH  2), 127.69 (CH  2), 107.7 (C), 77.4 (CH), 76.4
(CH), 69.8 (CH), 65.1 (CH2), 31.9 (CH2), 29.8 (CH2), 29.7 (CH2 
3), 29.64 (CH2  2), 29.61 (CH2), 29.59 (CH2), 29.56 (CH2), 29.4
(CH2), 27.3 (CH3), 26.8 (CH3  3), 26.7 (CH2), 25.1 (CH3), 22.7
(CH2), 19.2 (C), 14.1 (CH3); HRMS (ESI, M + Na
+) calcd for
C37H60O4NaSi 619.4153, found 619.4131.This journal is © The Royal Society of Chemistry 2014(2S,3S,4R)-2-Azido-3,4-O-isopropylidene-octadecan-1,3,4-
triol (6)
Method A. To a solution of the azide 11 (166 mg, 0.27 mmol)
in THF (12 mL) was added TBAF (540 mL, 0.54 mmol, 1 M) at
30 C for 1 h. The reaction mixture was diluted with water and
extracted with EtOAc (3 10 mL). The organic layer was washed
with brine (15 mL), dried over anhydrous MgSO4, ltered, and
concentrated in vacuo. The residue was puried by column
chromatography on silica gel to give the alcohol 6 (94 mg) in
92% yield as a white solid.
Method B. To a stirring solution of alcohol 15 (185 mg, 0.31
mmol) and triphenylphosphine (244 mg, 0.93 mmol) in anhy-
drous tetrahydrofuran (2 mL) at 0 C were slowly added diiso-
propyl azodicarboxylate (DIAD, 183 mL, 0.93 mmol) and
diphenyl phosphonyl azide (DPPA, 214 mL, 0.93 mmol). Aer
stirring for 3 h at room temperature, the solvent was removed in
vacuo. The residue was dissolved in tetrahydrofuran (2 mL). The
mixture solution was treated with tetra-n-butylammonium
uoride (1 M in tetrahydrofuran, 2.5 mL, 2.48 mmol, TBAF) and
stirred overnight. The solvent was removed under reduced
pressure, and the residue was puried by column chromatog-
raphy on silica gel to aﬀord 6 (73 mg, 61%) as a white solid. Rf
0.55 (EtOAc/Hex¼ 1/4); [a]25D +23.70 (c 1.0, CH2Cl2); mp 33 C; IR
(CH2Cl2) v 3425, 2990, 2925, 2854, 2098, 1461, 1372, 1247, 1219,
1170, 1066 cm1; 1H NMR (600 MHz, CDCl3) d 4.18 (ddd, J¼ 9.6,
6.0, 4.2 Hz, 1H, H-4), 4.01–3.96 (m, 2H, H-1a, H-3), 3.87 (dd, J ¼
11.4, 5.4 Hz, 1H, H-1b), 3.47 (ddd, J ¼ 9.6, 5.4, 4.2 Hz, 1H, H-2),
1.64–1.53 (m, 3H, H-5a, H-5b, CH2), 1.43 (s, 3H, CH3), 1.40–1.26
(m, 27H, CH2, CH3), 0.88 (t, J ¼ 6.6 Hz, 3H, CH3); 13C NMR (150
MHz, CDCl3) d 108.4 (C), 77.1 (CH), 76.7 (CH), 63.9 (CH2), 61.1
(CH), 31.9 (CH2), 29.7 (CH2  3), 29.6 (CH2  4), 29.5 (CH2  1),
29.4 (CH2  2), 28.0 (CH3), 26.5 (CH2), 25.5 (CH3), 22.7 (CH2),
14.1 (CH3); HRMS (APCI, M + H
+) calcd for C21H42N3O3
356.3159, found 356.3171.
(2S,3S,4R)-2-Azido-1-O-(2,3-di-O-acetyl-4,6-O-benzylidene-b-
D-glucopyranosyl)-3,4-O-isopropylidene-octadecan-1,3,4-triol
(16a)
Method A. A solution of thioglucoside 7a (115 mg, 0.25 mmol)
and primary alcohol 6 (73 mg, 0.19 mmol) in DCM (2 mL) was
stirred for 1 h at room temperature with activated 4 A˚ molecular
sieves (188 mg). Aer cooling to 20 C, NIS (110 mg, 0.49
mmol) and TfOH (7.0 mL, 0.08 mmol) were added, and reaction
mixture was stirred for 2 h. When the reaction was completed,
molecular sieves were removed by ltration through celite. The
ltrate was extracted with aqueous Na2S2O3 (15 mL) and brine
(15 mL), and the organic layers were dried over anhydrous
MgSO4, ltered, and concentrated. It was puried by column
chromatography on silica gel to give the desired product 16a (52
mg, 38%) as a white solid.
Method B. A solution of imidate 7b (70 mg, 0.14 mmol) and
primary alcohol 6 (42 mg, 0.11 mmol) in DCM (1mL) was stirred
for 30 min at room temperature with activated 3 A˚ molecular
sieves (70 mg). Aer cooling to 20 C, TMSOTf (2.0 mL, 0.01
mmol) was added. When the reaction was completed, molecular
sieves were removed by ltration through celite. The ltrate was
extracted with DCM (3  15 mL), and the organic layers wereRSC Adv., 2014, 4, 47752–47761 | 47757
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View Article Onlinedried over anhydrous MgSO4, ltered, and concentrated. It was
puried by column chromatography on silica gel to give the
compound 16a (27mg, 36%) as a white solid. Rf 0.30 (EtOAc/Hex
¼ 1/6); [a]22D 33.4 (c 1.0, CH2Cl2); mp 81 C; IR (CH2Cl2) v 2924,
2854, 2100, 1755, 1639, 1458, 1317, 1238, 1218, 1176, 1099,
1064, 1032 cm1; 1H NMR (600 MHz, CDCl3) d 7.45–7.43 (m, 2H,
Ar–H), 7.37–7.35 (m, 3H, Ar–H), 5.51 (s, 1H, CHPh), 5.32 (t, J ¼
9.6 Hz, 1H, H-30), 5.07 (dd, J ¼ 9.0, 7.8 Hz, 1H, H-20), 4.69 (d, J ¼
7.8 Hz, 1H, H-10), 4.38 (dd, J ¼ 10.8, 5.4 Hz, 1H, H-6a0), 4.14
(ddd, J¼ 9.6, 5.4, 5.4 Hz, 1H, H-4), 4.06 (dd, J¼ 10.8, 7.2 Hz, 1H,
H-1a), 3.94 (dd, J ¼ 10.8, 3.0 Hz, 1H, H-1b), 3.87–3.81 (m, 2H, H-
3, H-6b0), 3.76 (t, J¼ 9.6 Hz, 1H, H-40), 3.56 (ddd, J¼ 9.6, 9.6, 5.4
Hz, 1H, H-50), 3.01 (ddd, J ¼ 10.2, 7.2, 3.0 Hz, 1H, H-2), 2.07 (s,
3H, CH3), 2.05 (s, 3H, CH3), 1.59–1.52 (m, 2H, H-5a, H-5b), 1.41
(s, 3H, CH3), 1.37–1.26 (m, 27H, CH3, CH2), 0.88 (s, 3H, CH3);
13C NMR (150 MHz, CDCl3) d 170.2 (C), 169.5 (C), 136.7 (C),
129.1 (CH), 128.2 (CH  2), 126.1 (CH  2), 108.3 (C), 101.5
(CH), 100.9 (CH), 78.1 (CH), 77.7 (CH), 75.3 (CH), 72.2 (CH), 71.8
(CH), 70.3 (CH2), 68.5 (CH2), 66.4 (CH), 59.4 (CH), 31.9 (CH2),
29.7 (CH2  3), 29.6 (CH2  4), 29.5 (CH2), 29.3 (CH2  2), 28.2
(CH3), 26.4 (CH2), 25.6 (CH3), 22.7 (CH2), 20.8 (CH3  2), 14.1
(CH3); HRMS (ESI, M + Na
+) calcd for C38H59O10N3Na 740.4093,
found 740.4112.
(2S,3S,4R)-2-Azido-1-O-(2-O-acetyl-3-O-benzyl-4,6-O-benzyli-
dene-b-D-glucopyranosyl)-3,4-O-isopropylidene-octadec-1,3,4-
triol (16b). A solution of thioglucoside 7c (166 mg, 0.34 mmol)
and primary alcohol 6 (100 mg, 0.26 mmol) in DCM (3 mL) was
stirred for 1 h at room temperature with activated 4 A˚ molecular
sieves (266 mg). Aer cooling to 20 C, NIS (153 mg, 0.68
mmol) and TfOH (9.0 mL, 0.10 mmol) were added, and the
reaction mixture was stirred for 2 h. When the reaction was
completed, molecular sieves were removed by ltration through
celite. The ltrate was extracted with aqueous Na2S2O3 (15 mL)
and brine (15 mL), and the organic layers were dried over
anhydrous MgSO4, ltered, and concentrated. The residue was
puried by column chromatography on silica gel to give the
desired product 16b (92 mg, 46%) as a white solid. Rf 0.35
(EtOAc/Hex ¼ 1/8); [a]22D 11.2 (c 1.0, CH2Cl2); mp 65 C; IR
(CH2Cl2) v 2924, 2853, 2099, 1753, 1456, 1428, 1312, 1174, 1098,
1067, 1030 cm1; 1H NMR (600 MHz, CDCl3) d 7.51–7.50 (m, 2H,
Ar–H), 7.42–7.38 (m, 3H, Ar–H), 7.33–7.31 (m, 2H, Ar–H), 7.23–
7.27 (m, 3H, Ar–H), 5.59 (s, 3H, CHPh), 5.09 (dd, J ¼ 9.0, 7.8 Hz,
1H, H-20), 4.88 (d, J ¼ 12.0 Hz, 1H, CH2Ph), 4.68 (d, J ¼ 12.0 Hz,
1H, CH2Ph), 4.57 (d, J ¼ 7.8 Hz, 1H, H-10), 4.38 (dd, J ¼ 10.2, 4.8
Hz, 1H, H-6a0), 4.13 (ddd, J ¼ 9.6, 5.4, 5.4 Hz, 1H, H-4), 4.03 (dd,
J ¼ 10.8, 7.2 Hz, 1H, H-1a), 3.91 (dd, J ¼ 10.8, 2.4 Hz, 1H, H-1b),
3.87–3.80 (m, 3H, H-3, H-40, H-6b0), 3.74 (t, J ¼ 9.0 Hz, 1H, H-30),
3.51–3.44 (m, 2H, H-2, H-50), 2.01 (s, 3H, CH3), 1.60–1.49 (m, 2H,
H-5a, H-5b), 1.40 (s, 3H, CH3), 1.37–1.26 (m, 27H, CH3, CH2),
0.88 (t, J ¼ 6.6 Hz, 3H, CH3); 13C NMR (150 MHz, CDCl3) d 169.3
(C), 138.1 (C), 137.1 (C), 129.0 (CH), 128.3 (CH 4), 127.8 (CH
2), 127.7 (CH), 126.0 (CH  2), 108.2 (C), 101.2 (CH), 101.1 (CH),
81.4 (CH), 78.4 (CH), 77.7 (CH), 75.3 (CH), 74.0 (CH2), 72.4 (CH),
69.8 (CH2), 68.6 (CH2), 66.3 (CH), 59.5 (CH), 31.9 (CH2), 29.7
(CH2  3), 29.6 (CH2  4), 29.3 (CH2  3), 28.2 (CH3), 26.5
(CH2), 25.6 (CH3), 22.7 (CH2), 20.9 (CH3), 14.1 (CH3); HRMS (ESI,
M + Na+) calcd for C43H63O9N3Na 788.4457, found 788.4475.47758 | RSC Adv., 2014, 4, 47752–47761(2S,3S,4R)-2-Azido-1-O-(2,3,4-tri-O-benzyl-b-D-glucopyrano-
syl)-3,4-O-isopropylidene-octadec-1,3,4-triol (17). A solution of
imidate 7d (790 mg, 1.28 mmol) and primary alcohol 6 (196 mg,
0.51 mmol) in the mixture of DCM and ACN (DCM/ACN ¼ 1/2,
10 mL) was stirred for 30 min at room temperature with acti-
vated 3 A˚ molecular sieves (196 mg). Aer cooling to 30 C,
TMSOTf (34 mL, 0.18 mmol) was slowly added. The reaction
mixture was stirred at this temperature for 5 min and then
warmed to room temperature. When the reaction was
completed, molecular sieves were removed by ltration through
celite. The ltrate was extracted with DCM (3  15 mL) and
water (15 mL). The organic layers were dried over anhydrous
MgSO4, ltered, and concentrated under vacuo. The residue was
puried by column chromatography on silica gel to give mixture
of spots of a-isomer, b-isomer, and acceptor 6. Separation of
theses a-isomer, b-isomers and acceptor 6 was diﬃcult in
column chromatography. However, to a solution of the spots
mixture in MeOH (4.5 mL) was added sodium methoxide (22
mg, 0.41 mmol) and stirred for 12 h. The solvent was removed,
and the residue was puried by column chromatography on
silica gel to aﬀord 17 (344 mg, 82%, b/a ¼ 3.2/1) as a colorless
oil. Rf 0.63 (EtOAc/Hex ¼ 1/4); [a]22D +22.5 (c 1.0, CH2Cl2); IR
(CH2Cl2) v 3467, 2922, 2851, 2099, 1496, 1456, 1361, 1259, 1217,
1147, 1083, 1030 cm1; 1H NMR (600 MHz, CDCl3) d 7.36–7.27
(m, 15H, ArH), 4.93 (d, J¼ 10.8 Hz, 1H, CH2Ph), 4.93 (d, J¼ 11.4
Hz, 1H, CH2Ph), 4.85 (d, J ¼ 10.8 Hz, 1H, CH2Ph), 4.82 (d, J ¼
11.4 Hz, 1H, CH2Ph), 4.63 (d, J ¼ 11.4 Hz, 1H, CH2Ph), 4.49 (d, J
¼ 7.8 Hz, 1H, H-10), 4.17–4.13 (m, 1H, H-4), 4.08 (dd, J ¼ 10.2,
7.2 Hz, 1H, H-1a), 4.00 (dd, J ¼ 10.8, 3.0 Hz, 1H, H-1b), 3.90 (dd,
J ¼ 9.6, 5.4 Hz, 1H, H-3), 3.86 (dd, J ¼ 12.0, 2.4 Hz, 1H, H-6a0),
3.70–3.66 (m, 2H, H-30, H-6b0), 3.55 (t, J ¼ 9.6 Hz, 1H, H-40),
3.50–3.46 (m, 2H, H-2, H-20), 3.40–3.37 (m, 1H, H-50), 1.64–1.51
(m, 4H, CH2), 1.40 (s, 3H, CH3), 1.37–1.26 (m, 27H, CH2, CH3),
0.88 (t, J ¼ 7.2 Hz, 3H, CH3); 13C NMR (150 MHz, CDCl3) d 138.4
(C  2), 137.9 (C), 128.5 (CH  2), 128.4 (CH  4), 128.1 (CH 
2), 127.9 (CH 3), 127.8 (CH 2), 127.7 (CH), 127.6 (CH), 108.7
(C), 103.4 (CH), 84.5 (CH), 82.5 (CH), 77.8 (CH), 77.6 (CH), 75.7
(CH2), 75.4 (CH), 75.1 (CH), 75.0 (CH2), 59.7 (CH), 31.9 (CH2),
29.7 (CH2  5), 29.6 (CH2  6), 29.4 (CH2), 29.3 (CH2), 28.2
(CH3), 26.6 (CH2), 25.6 (CH3), 22.7 (CH2), 14.1 (CH3); HRMS (ESI,
M + Na+) calcd for C48H69O8N3Na 838.4977, found 838.4981.
(Methyl 5-acetamido-7,8,9-tri-O-acetyl-3,5-dideoxy-D-glycero-
a-D-galacto-2-nonulopyranosylonate)-(2 / 6)-2,3,4-tri-O-ben-
zyl-b-D-glucopyranosyl-(1/ 1)-(2S,3S,4R)-2-azido-3,4-O-iso-propy
-lidene-octadecan-1,3,4-triol (18a)
Method A. A solution of donor 5a (56 mg, 0.09 mmol) and
primary alcohol 17 (63 mg, 0.08 mmol) in DCM/ACN (1/2 ratio,
10 mL) was stirred for 1 h at room temperature with activated 3
A˚ molecular sieves (180 mg). Aer cooling to 30 C, NIS (52
mg, 0.23 mmol) and TfOH (3 mL, 0.04 mmol) were added, and
the reaction mixture was stirred for 2 h. When the reaction was
completed, molecular sieves were removed by ltration through
celite. The ltrate was extracted with aqueous Na2S2O3 (10 mL)
and brine (10 mL), and the organic layers were dried over
anhydrous MgSO4, ltered, and concentrated to vacuo. The
residue was puried by column chromatography on silica gel toThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinegive the desired product 18a (86 mg, 86%, ab/bb ¼ 2.7/1) as a
white solid.
Method B. A solution of donor 5b (43 mg, 0.07 mmol) and
primary alcohol 17 (53 mg, 0.06 mmol) in a mixture of DCM and
ACN (1/2 ratio, 0.90 mL) was stirred for 1 h at room temperature
with activated 3 A˚ molecular sieves (140 mg). Aer cooling to
30 C, NIS (40 mg, 0.18 mmol) and TfOH (4 mL, 0.04 mmol)
were added, and the reaction mixture was stirred for 2 h. When
the reaction was completed, molecular sieves were removed by
ltration through celite. The ltrate was extracted with aqueous
Na2S2O3 (10 mL) and brine (10 mL), and the organic layers were
dried over anhydrous MgSO4, ltered, and concentrated to
vacuo. The residue was puried by column chromatography on
silica gel to give the desired product 18a (69 mg, 84%, ab/bb ¼
3.2/1) as a white solid.
Method C. A solution of donor 5c (63 mg, 0.10 mmol) and
primary alcohol 17 (68 mg, 0.08 mmol) in DCM/ACN (1/2 ratio,
11 mL) was stirred for 1 h at room temperature with activated 3
A˚ molecular sieves (200 mg). Aer cooling to 30 C, AgOTf (86
mg, 0.33mmol) was added, and the reactionmixture was stirred
for 21 h. When the reaction was completed, molecular sieves
were removed by ltration through celite. The ltrate was
extracted with aqueous NaHCO3 (10 mL) and brine (10 mL), and
the organic layers were dried over anhydrous MgSO4, ltered,
and concentrated to vacuo. The residue was puried by column
chromatography on silica gel to give the desired product 18a (31
mg, 29%, ab/bb¼ 2.6/1) as a white solid. Rf 0.69 (EtOAc/Hex¼ 5/
1); [a]24D +1.8 (c 1.0, CH2Cl2); IR (CH2Cl2) v 3033, 2925, 2854,
2099, 1748, 1666, 1528, 1456, 1367, 1305, 1276, 1220, 1131,
1070, 1048 cm1; 1H NMR (600 MHz, CDCl3) d 7.35–7.27 (m,
15H, ArH), 5.41 (ddd, J¼ 9.6, 5.4, 3.0 Hz, 1H, H-80 0), 5.31 (dd, J¼
9.6, 2.4 Hz, 1H, H-70 0), 5.14 (d, J ¼ 10.2 Hz, 1H, NH), 4.92–4.75
(m, 7H, H-40 0, CH2Ph), 4.40 (d, J¼ 7.8 Hz, 1H, H-10), 4.21 (dd, J¼
13.2, 2.4 Hz, 1H, H-9a0 0), 4.17 (dd, J ¼ 11.4, 4.8 Hz, 1H, H-6a0),
4.13 (ddd, J¼ 9.6, 5.4, 3.0 Hz, 1H, H-4), 4.09 (dd, J¼ 10.8, 1.8 Hz,
1H, H-60 0), 4.07–4.02 (m, 2H, H-1a, H-50 0), 3.98 (dd, J ¼ 12.6, 5.4
Hz, 1H, H-9b00), 3.90 (dd, J ¼ 10.8, 3.0 Hz, 1H, H-1b), 3.79 (dd, J
¼ 9.6, 6.0 Hz, 1H, H-3), 3.77 (s, 3H, CH3), 3.68 (t, J ¼ 9.0 Hz, 1H,
H-40), 3.63–3.57 (m, 3H, H-2, H-30, H-6b0), 3.46 (dd, J ¼ 9.0, 7.8
Hz, 1H, H-20), 3.41 (ddd, J¼ 5.4, 4.2, 1.8 Hz, 1H, H-50), 2.68 (dd, J
¼ 12.6, 4.8 Hz, 1H, H-3a00), 2.13 (s, 3H, CH3), 2.029 (s, 3H, CH3),
2.026 (s, 3H, CH3), 1.99–1.94 (m, 4H, H-3b0 0, CH3), 1.87 (s, 3H,
CH3), 1.59–1.51 (m, 2H, CH2), 1.42 (s, 3H, CH3), 1.38–1.26 (m,
27H, CH2, CH3), 0.88 (t, J ¼ 7.2 Hz, 3H, CH3); 13C NMR (150
MHz, CDCl3) d 171.0 (C), 170.6 (C), 170.3 (C), 170.0 (C), 169.8 (C),
167.9 (C), 138.6 (C), 138.5 (C), 138.4 (C), 128.4 (CH  4), 128.3
(CH  3), 128.1 (CH  2), 127.9 (CH  2), 127.8 (CH  2), 127.6
(CH  2), 108.4 (C), 103.7 (CH), 98.7 (C), 84.4 (CH), 82.3 (CH),
77.8 (CH), 77.2 (CH), 75.8 (CH), 75.7 (CH2), 74.9 (CH2), 74.0
(CH), 72.2 (CH), 70.7 (CH2), 69.1 (CH), 67.9 (CH), 66.9 (CH), 63.5
(CH2), 62.1 (CH2), 60.5 (CH), 52.6 (CH3), 49.4 (CH), 38.1 (CH2),
31.9 (CH2), 29.7 (CH2  4), 29.6 (CH2  4), 29.5 (CH2), 29.4
(CH2), 29.3 (CH2), 28.2 (CH3), 26.5 (CH2), 25.6 (CH3), 23.2 (CH3),
22.7 (CH2), 21.1(CH3), 20.8 (CH3), 20.7 (CH3), 20.6 (CH3), 14.1
(CH3); HRMS (ESI, M + Na
+) calcd for C68H96O20N4Na 1311.6510,
found 1311.6552.This journal is © The Royal Society of Chemistry 2014(Methyl 5-tert-butyl carbonate acetamido-7,8,9-tri-O-acetyl-
3,5-dideoxy-D-glycero-a-D-galacto-2-nonulopyranosylonate)-(2
/ 6)-2,3,4-tri-O-benzyl-b-glucopyranosyl-(1 / 1)-(2S,3S,4R)-2-
azido-3,4-isopropylidene-octadecane-1,3,4-triol (18b). A solu-
tion of donor 5d (63 mg, 0.10 mmol) and primary alcohol 17 (71
mg, 0.09 mmol) in DCM/ACN (1/2 ratio, 1.2 mL) was stirred for 1
h at room temperature with activated 3 A˚ molecular sieves (200
mg). Aer cooling to 30 C, NIS (59 mg, 0.26 mmol) and TfOH
(8 mL, 0.04 mmol) were added, and the reaction mixture was
stirred for 3 h. When the reaction was completed, molecular
sieves were removed by ltration through celite. The ltrate was
extracted with aqueous Na2S2O3 (10 mL) and brine (10 mL), and
the organic layers were dried over anhydrous MgSO4, ltered,
and concentrated to vacuo. The residue was puried by column
chromatography on silica gel to give the desired product 18b (93
mg, 77%, ab/bb¼ 2/1) as a white solid. Rf 0.15 (EtOAc/Hex¼ 1/3);
[a]25D +13.57 (c 2.1, CH2Cl2); IR (CH2Cl2) v 3032, 2982, 2926, 2855,
2112, 1748, 1706, 1456, 1369, 1230, 1076, 1038 cm1; 1H NMR
(600 MHz, CDCl3) d 7.35–7.27 (m, 15H, ArH), 5.39–5.35 (m, 2H,
H-40 0, H-80 0), 5.16 (dd, J ¼ 8.4, 1.2 Hz, 1H, H-50 0), 4.92–4.74 (m,
7H, H-70 0, CH2Ph), 4.70 (dd, J¼ 10.2, 1.8 Hz, 1H, H-60 0), 4.40 (d, J
¼ 7.8 Hz, 1H, H-10), 4.26 (dd, J ¼ 12.6, 2.4 Hz, 1H, H-9a00), 4.18–
4.11 (m, 2H, H-6a0, H-4), 4.05 (dd, J ¼ 10.8, 9.0 Hz, 1H, H-1a),
3.94–3.88 (m, 2H, H-9b0 0, H-1b), 3.80 (dd, J ¼ 7.5 Hz, 1H, H-3),
3.77 (s, 3H, CH3), 71–3.56 (m, 4H, H-6b, H-40, H-30, H-2), 3.48–
3.44 (dd, J ¼ 13.8, 6.0 Hz, 1H, H-20), 3.41–3.38 (ddd, J ¼ 9.6, 3.6,
1.2 Hz, 1H, H-50), 2.82 (dd, J ¼ 12.6, 4.8 Hz, 1H, H-3a0 0), 2.35 (s,
3H, CH3), 2.15 (s, 3H, CH3), 2.00 (s, 3H, CH3), 1.97–1.93 (m, 4H,
H-3b0 0, CH3), 1.86 (s, 3H, CH3), 1.57–1.52 (m, 11H, NHBoc, CH2),
1.42 (s, 3H, CH3), 1.37–1.25 (m, 27H, CH2, CH3), 0.88 (t, J ¼ 7.2
Hz, 3H, CH3);
13C NMR (150 MHz, CDCl3) d 173.9 (C), 170.6 (C),
170.1 (C), 169.9 (C), 169.8 (C), 167.7 (C), 151.8 (C), 138.6 (C),
138.5 (C), 138.4 (C), 128.33 (CH 4), 128.30 (CH 3), 128.1 (CH
 2), 127.84 (CH  2), 127.75 (CH  2), 127.6 (CH  2), 127.5
(CH), 108.3 (C), 103.6 (CH), 98.7 (C), 84.6 (CH), 84.5 (CH), 82.3
(CH), 77.8 (CH), 77.1 (CH), 75.8 (CH), 75.6 (CH2), 74.9 (CH2),
73.9 (CH), 71.0 (CH2), 68.1 (CH), 66.7 (CH), 66.5 (CH), 60.5 (CH),
52.6 (CH3), 52.4 (CH), 31.9 (CH2), 29.7 (CH2  4), 29.64 (CH2 
4), 29.60 (CH2), 29.57 (CH2), 29.4 (CH2), 29.3 (CH2), 28.2 (CH3),
27.9 (CH3), 27.8 (CH3  4), 26.7 (CH3), 26.4 (CH2), 25.6 (CH3),
22.7 (CH2), 21.2 (CH3), 20.9 (CH3), 20.8 (CH3), 20.7 (CH3), 20.6
(CH3), 14.1 (CH3); HRMS (ESI, M + Na
+) calcd for
C73H104O22N4Na 1411.7034, found 1411.7064.
(Methyl 5-acetamido-7,8,9-tri-O-acetyl-3,5-dideoxy-D-glycero-
a-D-galacto-2-nonulopyranosylonate)-(2 / 6)-2,3,4-tri-O-ben-
zyl-b-D-glucopyranosyl-(1/ 1)-(2S,3S,4R)-3,4-isopropylidene-2-
octadecanoylaminooctadecane-1,3,4-triol (19). To a solution of
azide 18a (70 mg, 0.05 mmol) in THF (3.5 mL) was added tri-
phenylphosphine (26 mg, 0.10 mmol) at 0 C, and then the
reaction mixture was stirred at 0 C for 5 min. Aer addition of
water (4 mL, 0.23 mmol) at 0 C, the reaction mixture was heated
at 50 C for 12 h and then concentrated under reduced pressure.
The residue was used in the next step without further puri-
cation. Stearic acid (20 mg, 0.07 mmol), HOBt (19 mg, 0.10
mmol) and EDC (13 mg, 0.10 mmol) were added to a solution of
amine in DCM (3.40 mL). The reaction mixture was stirred for 4RSC Adv., 2014, 4, 47752–47761 | 47759
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View Article Onlinedays at room temperature and then concentrated under
reduced pressure to form a residue, which was puried by
column chromatography on silica gel to give the product 19 (42
mg, 51%). Rf 0.54 (EtOAc/Hex ¼ 3/1); [a]24D +12.0 (c 1.0, CH2Cl2);
IR (CH2Cl2) v 3420, 3064, 3031, 2915, 2871, 1740, 1640, 1496,
1453, 1362, 1236, 1146, 1070, 1029 cm1; 1H NMR (600 MHz,
CDCl3) d 7.35–7.28 (m, 15H, ArH), 5.84 (d, J ¼ 9.6 Hz, 1H, NH),
5.38 (ddd, J¼ 9.0, 4.8, 2.4 Hz, 1H, H-80 0), 5.30 (dd, J¼ 9.0, 1.8 Hz,
1H, H-70 0), 5.13 (d, J ¼ 9.6 Hz, 1H, NHAc), 4.94 (d, J ¼ 10.8 Hz,
1H, CH2Ph), 4.89–4.83 (m, 4H, H-40 0, CH2Ph), 4.76 (d, J ¼ 10.2
Hz, 1H, CH2Ph), 4.75 (d, J¼ 10.8 Hz, 1H, CH2Ph), 4.24 (d, J¼ 7.8
Hz, 1H, H-10), 4.20–4.15 (m, 3H, H-1a, H-6a0, H-9a0 0), 4.10–4.02
(m, 3H, H-2, H-500, H-60 0), 3.96–3.87 (m, 3H, H-3, H-4, H-9b0 0),
3.76 (s, 3H, CH3), 3.67–3.60 (m, 2H, H-30, H-40), 3.55–3.53 (m,
2H, H-1b, H-6b0), 3.45 (t, J ¼ 8.4 Hz, 1H, H-20), 3.38 (dd, J ¼ 9.6,
3.0 Hz, 1H, H-50), 2.66 (dd, J ¼ 12.6, 4.2 Hz, 1H, H-3a0 0), 2.13 (s,
3H, CH3), 2.034 (s, 3H, CH3), 2.029 (s, 3H, CH3), 1.96 (t, J ¼ 12.6
Hz, 1H, H-3b0 0), 1.90 (s, 3H, CH3), 1.87 (s, 3H, CH3), 1.80–1.76
(m, 4H, CH2), 1.48–1.42 (m, 4H, CH2), 1.40 (s, 3H, CH3), 1.34 (s,
3H, CH3), 1.31–1.18 (m, 50H, CH2), 0.88 (t, J ¼ 7.2, 6.0 Hz, 6H,
CH3);
13C NMR (150 MHz, CDCl3) d 172.5 (C), 171.0 (C), 170.6
(C), 170.2 (C), 169.9 (C), 169.8 (C), 167.9 (C), 128.6 (CH  2),
128.4 (CH  4), 128.1 (CH), 128.0 (CH  4), 127.8 (CH  3),
127.7 (CH), 107.9 (C), 104.6 (CH), 98.7 (C), 84.9 (CH), 82.2 (CH),
77.6 (CH  2), 75.7 (CH), 75.4 (CH2), 74.9 (CH2), 74.0 (CH), 72.3
(CH), 70.6 (CH2), 69.0 (CH), 67.8 (CH), 66.9 (CH), 63.4 (CH2),
62.1 (CH2), 52.7 (CH3), 49.4 (CH), 48.4 (CH), 38.1 (CH2), 36.5
(CH2), 31.9 (CH2  2), 29.7 (CH2  14), 29.5 (CH2  2), 29.4
(CH2), 29.3 (CH2  2), 28.1 (CH3), 26.4 (CH2), 25.9 (CH3), 25.7
(CH2), 23.2 (CH3), 22.7 (CH2  2), 21.1 (CH3), 20.8 (CH3  2),
20.5 (CH3), 14.1 (CH3  2); HRMS (ESI, M + H+) calcd for
C86H133O21N2 1529.9395, found 1529.9425.
(5-Acetamido-3,5-dideoxy-D-glycero-a-D-galacto-2-nonulopy-
ranosyloic-acid)-(2/ 6)-b-D-glucopyranosyl-(1/ 1)-(2S,3S,4R)-
2-octadecanoylaminoheotadecan-1,3,4-triol (1). To a solution of
trisaccharide derivative 19 (74 mg, 0.05 mmol) in methanol (2
mL) was added NaOH (1 mL, 1 N). The reaction mixture was
stirred at 50 C. Aer 1 h, the reaction mixture was concentrated
under reduced pressure without further purication to get the
residue. The residue (45 mg) was dissolved in a mixed solvent of
MeOH/CHCl3 (3/1 ratio, 0.60 mL) at room temperature. The
Pd(OH)2/C (45 mg, Degussa type) was added to the solution
followed by addition of three drops of acetic acid. The reaction
vessel was purged with hydrogen gas, and the mixture was
stirred under 60 psi pressure at room temperature for 5 h. The
resulting solution was ltered through celite, and the ltrate
was concentrated in vacuo. Several attempts to purify the target
compound 1 using column chromatography with various
solvent systems were unsuccessful. However, we developed a
simple technique to purify the target compound 1. A vertical
glass column was packed using 29.26 g of silica gel 60 (230–400
mesh, E. Merck) in the CHCl3 mobile phase. The crude
compound of 1 (45 mg) in a 3mLmixture solution of MeOH and
CHCl3 ¼ 1/3 was placed inside the top of the vertical glass
column. Then 200 mL eluent (MeOH/CHCl3, 50 mL/150 mL)
was used as the eluting solvent, owing down through the
column. Subsequently, the eluent phase was changed to47760 | RSC Adv., 2014, 4, 47752–47761(MeOH/CHCl3/H2O, 50 mL/150 mL/5 mL) so that the impurity
could be removed easily. The nal eluent solvent (MeOH/CHCl3/
H2O, 50 mL/150 mL/10 mL) was loaded in the vertical column
solvent reservoir, and the solvent phase in the column became a
heterogeneous mixture (lower MeOH/CHCl3 layer and higher
H2O layer). The higher H2O layer were removed by pipetting,
and the remaining homogenous layer was used as the eluting
solvent, owing down through the column to get highly pure
target compound 1 (15 mg, 85%). Rf 0.54 (MeOH/CHCl3/H2O ¼
1/2.4/0.2); [a]25D 2.4 (c 0.25, MeOH); IR (KBr) v 3316, 2926, 2850,
1632, 1552, 1466, 1383, 1135, 1036 cm1; 1H NMR (600 MHz,
CD3OD) d 4.24 (d, J ¼ 7.8 Hz, 1H, H-10), 4.13–4.07 (m, 2H, H-800,
H-9a0 0), 4.01 (dd, J ¼ 10.8, 4.8 Hz, 1H, H-6a0), 3.86 (ddd, J ¼ 9.0,
6.0, 3.0 Hz, 1H, H-50 0), 3.81 (dd, J ¼ 11.4, 2.4 Hz, 1H, H-1a), 3.74
(dd, J ¼ 10.8, 2.4 Hz, 1H, H-6b0), 3.71–3.64 (m, 4H, H-3, H-400, H-
70 0, H-9b00), 3.61 (dd, J ¼ 11.4, 5.4 Hz, 1H, H-1b), 3.56–3.49 (m,
3H, H-2, H-4, H-600), 3.42 (t, J ¼ 9.0 Hz, 1H, H-40), 3.36–3.32 (m,
2H, H-30, H-50), 3.20 (t, J¼ 8.4 Hz, 1H), 2.84 (dd, J¼ 12.0, 3.6 Hz,
1H, H-3a00), 2.22–2.20 (m, 2H, CH2), 2.01 (s, 3H, CH3), 1.63–1.52
(m, 5H, H-3b0 0, CH2), 1.45–1.42 (m, 2H, CH2), 1.30 (bs, 50H,
CH2), 0.89 (t, J¼ 6.6 Hz, 6H); 13C NMR (150 MHz, CDCl3) d 176.0
(C), 175.6 (C), 174.2 (C), 104.7 (CH), 101.5 (C), 77.6 (CH), 76.4
(CH), 75.1 (CH), 74.7 (CH), 74.3 (CH), 72.9 (CH), 72.8 (CH), 71.3
(CH), 70.2 (CH  1, CH2  1), 69.4 (CH), 64.4 (CH2), 64.1 (CH2),
54.2 (CH), 52.0 (CH), 42.5 (CH2), 37.3 (CH2), 33.1 (CH2 2), 31.9
(CH2), 31.0 (CH2  2), 30.9 (CH2  7), 30.8 (CH2  5), 30.7 (CH2
 2), 30.53 (CH2  2), 30.50 (CH2  2), 30.45 (CH2  2), 27.2
(CH2), 23.8 (CH2  1, CH3  1), 22.6 (CH2), 14.5 (CH3  2);
HRMS (ESI, M + Na+) calcd for C53H100O17N2Na 1059.6914,
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